Ciechanowicz A, Miks B, Kawiak J, Ciechanowski K, Ryszkiewicz D, Długosz A, Syczewska-Wawrzynowicz M, Marzecka J, Czekalski S
Zakład Biochemii Klinicznej i Diagnostyki Laboratoryjnej Pomorskiej Akademii Medycznej w Szczecinie.
Pol Arch Med Wewn. 1995 Nov;94(5):395-401.
Plasma prekallikrein (PPK) is a single-chain glycoprotein synthesized in the liver. The aim of our study was to evaluate a plasma prekallikrein as the marker reflecting liver protein synthesis in patients with chronic liver diseases. PPK levels have been measured by own modification of amidolytic micro-assay in 43 patients with chronic liver diseases and 37 healthy volunteers as control group. As compared to control group, PPK level was significantly decreased in patients with chronic active hepatitis and with decompensated liver cirrhosis and significantly increased in patients with liver cirrhosis complicated by hepatocellular carcinoma. There was no difference in plasma prekallikrein between patients with compensated liver cirrhosis and controls. The results suggest that PPK might be a useful index for the assessment of residual functional liver mass in patients with chronic liver diseases.
血浆前激肽释放酶（PPK）是一种在肝脏中合成的单链糖蛋白。我们研究的目的是评估血浆前激肽释放酶作为反映慢性肝病患者肝脏蛋白质合成的标志物。采用自行改良的酰胺分解微量测定法，对43例慢性肝病患者和37名健康志愿者作为对照组进行了PPK水平测定。与对照组相比，慢性活动性肝炎和失代偿期肝硬化患者的PPK水平显著降低，而肝硬化合并肝细胞癌患者的PPK水平显著升高。代偿期肝硬化患者与对照组之间的血浆前激肽释放酶水平无差异。结果表明，PPK可能是评估慢性肝病患者残余功能性肝质量的有用指标。
